NHS England to Offer New Non-Hormonal Drug for Menopausal Hot Flushes
In a significant development for women's healthcare, the NHS in England is set to provide a groundbreaking drug to prevent hot flushes, a common symptom of menopause. The treatment, known as Veoza or fezolinetant, has received approval from the National Institute for Health and Care Excellence, marking a pivotal moment for those unable to use hormone replacement therapy.
Addressing a Widespread Health Concern
Hot flushes, medically termed vasomotor symptoms, impact approximately 70% of women undergoing menopause. These sudden and intense sensations of heat can severely disrupt daily life, affecting sleep patterns, physical activity, work productivity, and overall quality of life. Despite the prevalence of this condition, safe and effective treatment alternatives have been limited for decades.
Hormone replacement therapy remains the most effective option for managing moderate to severe symptoms, but it is not suitable for all women. Individuals with a history of breast or ovarian cancer, blood clots, or untreated high blood pressure often cannot use HRT. Additionally, some women experience adverse side effects or simply prefer non-hormonal approaches to treatment.
How the New Treatment Works
Veoza, developed by Astellas Pharma, offers a novel solution by targeting the brain's nerve pathways. The drug is administered as a 45mg tablet taken once daily and works by blocking the neural signals that trigger hot flushes and night sweats. This mechanism provides a non-hormonal alternative, addressing a critical gap in menopause care.
Helen Knight, director of medicines evaluation at Nice, emphasized the importance of this approval. She stated, "We know that menopausal hot flushes and night sweats can have a profound impact on quality of life and significantly affect overall wellbeing. For those who are unable to take HRT for varying reasons, options have historically been limited, and we have heard clearly from patients how difficult that can be."
Eligibility and Impact
It is estimated that over 500,000 women in England will be eligible to benefit from this treatment. The decision to approve fezolinetant was based on evidence showing its effectiveness in reducing symptoms and its cost-effectiveness, ensuring value for taxpayers.
Dr. Sue Mann, national clinical director in women's health for NHS England, welcomed the news, saying, "Symptoms of menopause including hot flushes and night sweats can affect every part of a woman's life, so this is very welcome news especially for women who are unable to or don't wish to take hormone replacement therapy. It's another vital treatment option, which could help hundreds of thousands of women experiencing menopause to better manage their symptoms and feel more in control of their health."
While HRT continues to be the first-line treatment for many, the availability of fezolinetant on the NHS represents a crucial step forward in providing comprehensive care for menopausal women. This development underscores the ongoing efforts to expand treatment options and improve health outcomes for women across England.
